In early April 2012, Michelle Dipp, MD, Ph.D, CEO and co-founder of OvaScience, had just received a buyout offer from PG Ventures, a private equity firm interested in acquiring the innovative fertility treatments company. The company's first promising fertility treatment, AUGMENT (Autologous Germ-line Mitochondrial Energy Transfer), had the potential to improve egg quality, increase the success of IVF cycles, and decrease the incidence of multiple births (i.e., twins, triplets). OvaScience had been in operation since 2011, and AUGMENT had not yet reached the market. Dipp and her partners had high hopes for the success of AUGMENT and the impact the underlying technology could have on millions of infertility cases around the world. How fast might Dipp and her team grow OvaScience? Would they have the resources? Dipp considered the best way to build out OvaScience's business model and whether AUGMENT's potential outweighed the PG Ventures offer.

A unique probiotic formulation, L-39, has great promise as a pharmaceutical treatment for a common illness. When it hits a stumbling block in its latest clinical trial, Hilde Dach, the scientist leading the research at German drug maker Caliska, faces the prospect that the company may want to reimagine her product as a nutraceutical, because the regulatory hurdles would be easier to clear. Is the company merely hedging its bets to avoid big losses, or is it abandoning the possibility of achieving loftier aims and potentially bigger profits? Expert commentary comes from Jonathan Lewis, CEO of Ziopharm Oncology, and Colin Hill, president of the International Scientific Association for Probiotics and Prebiotics.

A unique probiotic formulation, L-39, has great promise as a pharmaceutical treatment for a common illness. When it hits a stumbling block in its latest clinical trial, Hilde Dach, the scientist leading the research at German drug maker Caliska, faces the prospect that the company may want to reimagine her product as a nutraceutical, because the regulatory hurdles would be easier to clear. Is the company merely hedging its bets to avoid big losses, or is it abandoning the possibility of achieving loftier aims and potentially bigger profits? Expert commentary comes from Jonathan Lewis, CEO of Ziopharm Oncology, and Colin Hill, president of the International Scientific Association for Probiotics and Prebiotics.

A unique probiotic formulation, L-39, has great promise as a pharmaceutical treatment for a common illness. When it hits a stumbling block in its latest clinical trial, Hilde Dach, the scientist leading the research at German drug maker Caliska, faces the prospect that the company may want to reimagine her product as a nutraceutical, because the regulatory hurdles would be easier to clear. Is the company merely hedging its bets to avoid big losses, or is it abandoning the possibility of achieving loftier aims and potentially bigger profits? Expert commentary comes from Jonathan Lewis, CEO of Ziopharm Oncology, and Colin Hill, president of the International Scientific Association for Probiotics and Prebiotics.

Describes a set of key strategic decisions facing the scientific founder and CEO of a promising, early stage bio-pharmaceuticals company. Should the company establish a proposed alliance with a pharmaceutical firm? Should it create a nutraceuticals business in parallel to its effort to develop anti-aging therapeutics? And, should it in-license a second drug development candidate?

An executive from pharmaceutical company GSK must choose how much to integrate a recently acquired biotechnology firm, Sirtris. Moncef Slaoui, GSK's global head of R&D, championed the acquisition of Sirtris to gain access to its potentially revolutionary science. Slaoui must balance the need to recoup shareholder value after paying a two-times premium for Sirtris with his desire to retain Christoph Westphal, Sirtris's co-founder and CEO, and other key individuals at the company. His desire to protect Sirtris from GSK's size and bureaucracy occurs in a period when GSK has launched major changes in its R&D organization, which focus on decentralizing and externalizing R&D, as well as revamping the resource allocation process to parallel more of a venture capital-based model. The case also explores the views of Christoph Westphal on the early challenges of the integration and the impact GSK was having on Sirtris. Can be used in conjunction with a separate case that focuses on Sirtris's business model.

Tennant, a leading producer of floor cleaning equipment, must determine the business model to use for its new chemical free cleaning technology. In 2005, Tennant Company had developed an innovative, environmentally friendly, cleaning technology that could potentially revolutionize cleaning. Historically, Tennant was a producer of floor and carpet washing machines for industrial and commercial markets. Over time, it became clear that the technology had applications far beyond Tennant's core markets. In mid-2009, the company set up a new venture to develop the technology's promise. In 2010 this venture was wholly owned by Tennant and run by a Tennant manager. The case examines the decisions the CEO and new venture head must make to best structure and position the venture to succeed.

Bill Strickland, CEO of Manchester Bidwell Corporation, must decide the best way to replicate his innovative, award-winning approach to curing poverty. Manchester Bidwell's approach, which provides both adult job-training tuned to fill the needs of local industries and after-school art instruction for at-risk youth, has proven highly effective over the 40 years Strickland has operated it. He wants to replicate this strategy across 100 or 200 cities, but progress has been slow. Is the current intensive approach correct, or should he change it? What would be at risk? How can he best provide his "cure for poverty" to the greatest number of communities?

In Feb. 2010, management of the Huffington Post, a fast-growing but not-yet-profitable Internet newspaper that aggregates blog posts from unpaid contributors and excerpts of stories originally published by other news sites, faces a number of decisions about its growth strategy. Foremost, Huffington Post management must determine whether to rely to a greater extent upon social networking technologies (e.g., Facebook, Twitter) to select and present the content delivered to specific users or continue to rely on human editors to play a curator role.

Tennant, a leading producer of floor cleaning equipment, must determine how to create, finance, structure, staff, govern, measure and manage a new venture for developing a fundamentally new product line. In 2005, Tennant Company had developed an innovative, environmentally friendly, cleaning technology that could potentially revolutionize cleaning. Historically, Tennant was a producer of floor and carpet washing machines for industrial and commercial markets. Over time, it became clear that the technology had applications far beyond Tennant's core markets. In mid-2009, the company set up a new venture to develop the technology's promise. In 2010 this venture was wholly owned by Tennant and run by a Tennant manager. The case examines the decisions the CEO and new venture head must make to best structure and position the venture to succeed.     

An executive from pharmaceutical company GSK must choose how much to integrate a recently acquired biotechnology firm, Sirtris. Moncef Slaoui, GSK's Global head of R&D, championed the acquisition of Sirtris to gain access to its potentially revolutionary science. Slaoui must balance the need to recoup shareholder value after paying a two-times premium for Sirtris with his desire to retain Christoph Westphal, Sirtris's co-founder and CEO, and other key individuals at the company. His desire to protect Sirtris from GSK's size and bureaucracy occurs in a period when GSK has launched major changes in its R&D organization, which focus on decentralizing and externalizing R&D, as well as revamping the resource allocation process to parallel more of a venture capital-based model. The case also explores the views of Christoph Westphal on the early challenges of the integration and the impact GSK was having on Sirtris. Can be used in conjunction with a separate case that focuses on Sirtris's business model.

A venture capitalist must decide whether to invest in a medical technology company that licenses intellectual property from a privately held IP holding company based on a platform technology. Entrepreneurs Amar Sawhney and Fred Khosravi founded Incept LLC to commercialize their multi-use hydrogel technology. The pair then spun off Confluent Surgical to develop some, but not all, of Incept's IP. The specifics of which IP Confluent would develop were described by a licensing agreement between Incept and Confluent. Venture capitalist Charles Warden of Schroder Ventures Life Sciences was deciding whether to invest in a Series A financing round in Confluent. Initially very excited about the deal, Warden becomes concerned about Confluent's valuation and its ability to succeed as a business when he learns about restrictions placed upon Confluent by the licensing agreement. The case describes Incept's business model and its approach to managing risk in early stage ventures. The case also addresses issues such as diversification and options preservation as well as the importance of trust and long-term relationships in decision-making in entrepreneurial arenas.

Biofuels start-up KiOR was developing a proprietary technology that had the potential to dramatically impact the emerging renewable energy landscape: a process that converted cellulosic biomass into "bio-crude," a hydrocarbon mixture with properties to those of crude oil. KiOR had been operating as a virtual organization, but with venture financing in place, founder and chief technology officer Paul O'Connor and the KiOR board needed to decide where to headquarter their business.

Yieldex Founder, Doug Cosman, is faced with the decision to sell his young software start-up for $4 million or to hire a CEO (Tom Shields) and pursue Series A venture capital financing. His angel investors and CEO candidate Tom Shields believe he should reject the offer and focus on building the company into a bigger enterprise. Cosman is attracted to the financial rewards offered by the potential acquirer.

Yieldex CEO Tom Shields was hired by the company's technical founder, Doug Cosman, in October 2007. One of Shields' top priorities is finding a vice president of engineering to manage the company's software development efforts. Shields and Costman disagree about the ideal profile of the new hire. Shields found a candidate that he likes, and he wonders about the implications of hiring the person against Cosman's wishes.

Describes a set of key strategic decisions facing the scientific founder and CEO of a promising, Early stage bio-pharmaceuticals company.l Should the company establish a proposed alliance with a pharmaceutical firm? Should it create a nutraceuticals business in parallel to its effort to develop anti-aging therapeutics? And, should it in-license a second drug development candidate?

In late 2002, global confectionery and beverage maker Cadbury Schweppes needed to decide whether or not to make an acquisition bid for Adams, an underperforming gum company which had been put up for sale by pharmaceutical giant Pfizer. Examining the decision from a strategic perspective, the (A) case provides brief histories of the two companies; traces the global confectionery industry, focusing especially on chocolate and gum; and details the analysis of the merger decision. The (B) case explores the specific identified synergies in-depth and provides an opportunity to judge their viability. The (C) and (D) cases conclude the story and update the case with issues facing the global confectionery leader in 2008.

In late 2002, global confectionery and beverage maker Cadbury Schweppes needed to decide whether or not to make an acquisition bid for Adams, an underperforming gum company which had been put up for sale by pharmaceutical giant Pfizer. Examining the decision from a strategic perspective, the (A) case provides brief histories of the two companies; traces the global confectionery industry, focusing especially on chocolate and gum; and details the analysis of the merger decision. The (B) case explores the specific identified synergies in-depth and provides an opportunity to judge their viability. The (C) and (D) cases conclude the story and update the case with issues facing the global confectionery leader in 2008.

In late 2002, global confectionery and beverage maker Cadbury Schweppes needed to decide whether or not to make an acquisition bid for Adams, an underperforming gum company which had been put up for sale by pharmaceutical giant Pfizer. Examining the decision from a strategic perspective, the (A) case provides brief histories of the two companies; traces the global confectionery industry, focusing especially on chocolate and gum; and details the analysis of the merger decision. The (B) case explores the specific identified synergies in-depth and provides an opportunity to judge their viability. The (C) and (D) cases conclude the story and update the case with issues facing the global confectionery leader in 2008.

In late 2002, global confectionery and beverage maker Cadbury Schweppes needed to decide whether or not to make an acquisition bid for Adams, an underperforming gum company which had been put up for sale by pharmaceutical giant Pfizer. Examining the decision from a strategic perspective, the (A) case provides brief histories of the two companies; traces the global confectionery industry, focusing especially on chocolate and gum; and details the analysis of the merger decision. The (B) case explores the specific identified synergies in-depth and provides an opportunity to judge their viability. The (C) and (D) cases conclude the story and update the case with issues facing the global confectionery leader in 2008.